Bill Amendment: IL HB4039 | 2025-2026 | 104th General Assembly

NOTE: For additional amemendments please see the Bill Drafting List

---

Bill Title: HOPE ACT

Status: 2026-04-17 - House Floor Amendment No. 2 Rule 19(c) / Re-referred to Rules Committee [HB4039 Detail]

Download: Illinois-2025-HB4039-House_Amendment_001.html

---

Rep. Lindsey LaPointe

Filed: 4/1/2026

 

 

 

10400HB4039ham001 LRB104 13076 BDA 35911 a
AMENDMENT TO HOUSE BILL 4039
AMENDMENT NO. ______. Amend House Bill 4039 by replacing
everything after the enacting clause with the following:
"Article 1. General Provisions
Section 1-1. Short title; references to Act.
(a) Short title. This Act may be cited as the Holistic
Overdose Prevention and Equity Act.
(b) References to Act. This Act may be referred to as the
HOPE Act.
Section 1-5. Legislative findings and purpose.
(a) The General Assembly finds that:
(1) The Department of Public Health reported 3,261
opioid-related overdose fatalities in 2022, representing
an estimated 272 lives lost every month as the State's
overdose crisis persists.

10400HB4039ham001 - 2 - LRB104 13076 BDA 35911 a
(2) The Cook County Medical Examiner's Office
confirmed that 2,000 opioid-related deaths occurred in
Cook County during 2022, with Black residents comprising
56% of deaths despite only representing 23% of the
county's population.
(3) The Opioid Data Dashboard provided by the
Department of Public Health vividly demonstrates the
extensive reach of opioid-related overdose across the
State; outside of Cook County, the counties that
experience the brunt of fatalities include Will County,
Winnebago County, DuPage County, Lake County, Kane County,
Madison County, St. Clair County, Sangamon County, McHenry
County, and Champaign County.
(4) Harm reduction measures have been proven to reduce
HIV transmissions, among other benefits, including
assisting in the prevention of the acquisition of other
bloodborne viruses such as Hepatitis B and C, the
prevention of fatal overdoses, decrease in encounters with
the criminal justice system, reduction in crime, reduction
of social exclusion for people who use drugs, and
improvement in access to medical care, mental health
support, housing, community support, food, and other basic
needs.
(5) Extensive research and reports continue to
demonstrate that harm reduction strategies not only save
lives by preventing overdose deaths but also limit

10400HB4039ham001 - 3 - LRB104 13076 BDA 35911 a
expenses in response to hospitalizations, emergency calls,
and deaths, promote public safety by diverting hazardous
waste from public spaces, and do not lead to an increase in
crime rates or substance use.
(6) Harm reduction operates on the understanding that
recovery is a multifaceted journey and that harm reduction
strategies complement traditional recovery approaches.
(7) While people who use drugs continue to face social
stigma, they still possess the right to receive access to
housing, education, economic mobility, mental health care,
and a range of services to support a better quality of
life.
(8) Harm reduction acknowledges the intersecting
systems of oppression that marginalize people who use
drugs and centers the need for racial, economic, and
gender justice within policies and practices.
(9) Across the State, harm reductionists tirelessly
dedicate themselves toward mitigating the harms of
substance use and providing critical support to
individuals in need, and it is essential to recognize and
appreciate the strain and labor undertaken by these
individuals as they endure secondary trauma and navigate
complex social, economic, and political landscapes.
(10) Recent reports have highlighted funding and other
stresses endured by harm reduction providers, including
inadequate and inefficient distribution of opioid

10400HB4039ham001 - 4 - LRB104 13076 BDA 35911 a
settlement funds, as reported in the Chicago Reader in
December 2024.
(b) It is the purpose of this Act to enhance harm reduction
through coordination of programs and policies; establishment
of a sustainable source of funding for harm reduction
programs, including potential provision of grants from the
Illinois Opioid Remediation State Trust Fund as appropriate;
and establishment of a permanent harm reduction
infrastructure.
Section 1-10. Definitions. In this Act:
"Department" means the Department of Public Health.
"FDA" means the federal Food and Drug Administration.
"Harm reduction" means a philosophical framework and set
of strategies designed to reduce harm and promote dignity and
well-being among persons and communities who engage in
substance use.
"Harm reduction professional" means a specialist who
engages directly with people who use drugs to prevent overdose
and infectious disease transmission; improve physical, mental,
and social well-being; and offer low-barrier options for
accessing health care services, including substance use and
mental health disorder treatment.
"Harm reduction provider" means an organization with a
needle and hypodermic syringe access program registered with
the Department of Public Health, as described in the Overdose

10400HB4039ham001 - 5 - LRB104 13076 BDA 35911 a
Prevention and Harm Reduction Act, where traditional harm
reduction services are the organization's primary focus, harm
reduction principles guide the organization, and the
organization has a long-standing, trusting relationship with
people who use drugs or are at risk of overdose in the
communities the organization serves.
"Medication-assisted treatment" means the use of
FDA-approved medications, in combination with counseling and
behavioral therapies, to provide a whole patient approach to
the treatment of substance use disorders.
"Medications for opioid use disorder" means the use of
FDA-approved medications to treat opioid use disorders.
"People with lived or living experience" means individuals
who currently or in the past have used drugs, been diagnosed
with a substance use disorder, experienced an overdose, or
used harm reduction services.
Article 2. Harm Reduction Advisory Board
Section 2-5. Purpose. The Harm Reduction Advisory Board is
created to advance the State's efforts to save lives through
harm reduction through improved alignment of existing efforts
across multiple State agencies, sustained and strategic
investment, and emphasis on input from people with lived or
living experience.

10400HB4039ham001 - 6 - LRB104 13076 BDA 35911 a
Section 2-10. Membership.
(a) Members of the Harm Reduction Advisory Board shall
represent the diversity of this State and possess the
expertise needed to perform the responsibilities of the Harm
Reduction Advisory Board. Members of the Harm Reduction
Advisory Board shall include the following:
(1) one member who is a representative of a statewide
coalition addressing harm reduction, appointed by the
Governor;
(2) one member who is a member of the General
Assembly, appointed by the President of the Senate;
(3) one member who is a member of the General
Assembly, appointed by the Speaker of the House of
Representatives;
(4) one member who is a member of the General
Assembly, appointed by the Minority Leader of the Senate;
(5) one member who is a member of the General
Assembly, appointed by the Minority Leader of the House of
Representatives;
(6) the Director of Public Health or the Director's
designee, who shall serve as co-chair;
(7) the Secretary of Human Services or the Secretary's
designee;
(8) the Chief Behavioral Health Officer or the Chief
Behavioral Health Officer's designee;
(9) the Statewide Opioid Settlement Administrator or

10400HB4039ham001 - 7 - LRB104 13076 BDA 35911 a
the Statewide Opioid Settlement Administrator's designee;
(10) one member who is a person with lived or living
experience with drug use, substance use disorder,
overdose, or use of harm reduction services, appointed by
the President of the Senate;
(11) one member who is a person with lived or living
experience with drug use, substance use disorder,
overdose, or use of harm reduction services, appointed by
the Speaker of the House of Representatives, who shall
serve as co-chair and serve as the Board's spokesperson,
including in communication with the General Assembly and
federal and local leaders;
(12) one member who is a person with lived or living
experience with drug use, substance use disorder,
overdose, or use of harm reduction services, appointed by
the Minority Leader of the Senate;
(13) one member who is a person with lived or living
experience with drug use, substance use disorder,
overdose, or use of harm reduction services, appointed by
the Minority Leader of the House of Representatives;
(14) one member who is a person who has lost an
immediate family member to a fatal overdose, appointed by
the Governor;
(15) one member who is a representative of a statewide
organization of behavioral health providers, appointed by
the Governor;

10400HB4039ham001 - 8 - LRB104 13076 BDA 35911 a
(16) one member who is a representative of a statewide
organization of addiction medicine specialists, appointed
by the Governor;
(17) two members who are employees of community-based
providers of harm reduction services, appointed by the
co-chairs;
(18) one member who is a person employed by a research
institution who has conducted research on harm reduction,
appointed by the co-chairs;
(19) seven members who are persons representing local
health departments, one from each Department region,
appointed by the Director of Public Health; and
(20) additional members who are persons with lived or
living experience with drug use, substance use disorder,
overdose, or use of harm reduction services as needed to
ensure that a majority of Harm Reduction Advisory Board
members have lived or living experience, appointed by the
co-chairs.
(b) Members of the Harm Reduction Advisory Board shall
serve without compensation, except that individuals with lived
or living experience under subsection (a) may receive stipends
as compensation for their time. Members of the Harm Reduction
Advisory Board may be reimbursed for reasonable expenses
incurred in the performance of their duties from funds
appropriated for that purpose.
(c) The Harm Reduction Advisory Board may take board

10400HB4039ham001 - 9 - LRB104 13076 BDA 35911 a
action, including holding meetings, upon the appointment of a
quorum of its members in compliance with the Open Meetings
Act. The Harm Reduction Advisory Board terms shall end 4 years
from the date of appointment.
Section 2-15. Meetings. The Harm Reduction Advisory Board
shall meet at least quarterly and may do so either in person or
remotely, in alignment with the Open Meetings Act. The
Department of Public Health and Department of Human Services
shall jointly provide administrative support.
Section 2-20. Responsibilities. Within 12 months after the
effective date of this Act, the Harm Reduction Advisory Board
shall:
(1) offer input on State agencies' processes to
solicit applications to ensure that harm reduction
providers are well-represented;
(2) provide input on the State's comprehensive,
interagency effort to ensure that harm reduction services
are available statewide, that the State-supported system
respects the dignity of people who use drugs, and that
investments in harm reduction services are sustained and
strategic;
(3) advise State agencies on a process to support
ongoing monitoring and evaluation of community-based harm
reduction programs;

10400HB4039ham001 - 10 - LRB104 13076 BDA 35911 a
(4) coordinate with harm reduction providers and other
community-based organizations; and
(5) deliver an annual report on successes and
challenges with the year's harm reduction funding and
recommendations for harm reduction public policy to the
General Assembly and to the Governor to be posted on the
Department of Public Health website.
Article 3. Grant Funding
Section 3-5. Grant-making authority.
(a) The Department of Public Health and the Department of
Human Services shall have grant-making, operational, and
procurement authority to distribute funds to harm reduction
providers to execute the functions established in this Act.
This subsection does not limit any existing grant-making,
operational, or procurement authorities of other State
agencies to distribute funds for harm reduction activities.
(b) The Department may issue grants to harm reduction
providers. Grants shall be issued on or before July 1 of each
fiscal year.
(c) Beginning in Fiscal Year 2028 and subject to
appropriation, grants shall be awarded for a project period of
one year, with 2 one-year renewals, contingent on Department
requirements for reporting and successful performance.
(d) The Department shall ensure that grants awarded under

10400HB4039ham001 - 11 - LRB104 13076 BDA 35911 a
this Act do not duplicate or supplant grants awarded under any
other Act. Grants awarded under this Act may be used to expand
existing services.
(e) The Department may make harm reduction grants to harm
reduction providers addressing opioid remediation in the
State. Eligible grant recipients shall be harm reduction
providers that offer services in a manner that supports and
meets the approved uses of the opioid settlement funds.
Eligible grant recipients have no entitlement to a grant under
this Section. The Department of Public Health shall partner
with the Department of Human Services to adopt rules to
implement this Section, if necessary, and may create a
competitive application procedure for grants to be awarded.
The rules may specify the manner of applying for grants;
grantee eligibility requirements; project eligibility
requirements; restrictions on the use of grant moneys; the
manner in which grantees must account for the use of grant
moneys; and any other provision that the Department of Public
Health determines to be necessary or useful for the
administration of this Section.
Section 3-10. Grants for harm reduction services.
(a) The Department may make grants to harm reduction
providers.
(b) When the Department issues grants, it shall ensure
that harm reduction services are available in all counties

10400HB4039ham001 - 12 - LRB104 13076 BDA 35911 a
whenever possible. A harm reduction provider may receive a
grant to provide harm reduction services in more than one
county.
(c) Harm reduction providers receiving grants under this
Act shall establish eligibility criteria for services in
alignment with the Department's requirements outlined in grant
agreements.
(d) An eligible participant shall not be court ordered to
receive services funded by a grant under this Act.
(e) Harm reduction providers receiving grants under this
Act shall provide the following harm reduction services
directly or through subgrants to other organizations:
(1) provision of harm reduction supplies, including,
but not limited to, overdose reversal supplies, including
naloxone kits with 3 milligram nasal spray, 4 milligram
nasal spray, and 0.4 milligram/milliliter intramuscular
formulation variations; condoms; supplies to promote
sterile injection and reduce infectious disease
transmission through injection drug use; safer smoking
kits to reduce infectious disease transmission; written
educational materials on safer injection practices and HIV
and viral hepatitis and prevention, testing, treatment,
and care services;
(2) overdose reversal education and training services;
(3) navigation services to ensure linkage to HIV and
viral hepatitis prevention, testing, treatment, and care

10400HB4039ham001 - 13 - LRB104 13076 BDA 35911 a
services, including antiretroviral therapy for HCV and
HIV, pre-exposure prophylaxis (PrEP), post-exposure
prophylaxis (PEP), prevention of mother-to-child
transmission, and partner services;
(4) referral to hepatitis A and hepatitis B
vaccinations;
(5) provision of education on HIV and viral hepatitis
prevention, testing, and referral to treatment services;
and
(6) provision of information on local resources or
referrals for PEP, or both.
(f) Harm reduction providers receiving grants under this
Act may provide the following services directly or through
subgrants to other organizations:
(1) provision of harm reduction supplies, including,
but not limited to, equipment, products, or materials to
analyze or test for the presence of a drug adulterant
within a controlled substance; safer sex kits; sharps
disposal and medication disposal kits; wound care
supplies; medication lock boxes; sterile water and saline;
ascorbic acid (vitamin C); nicotine cessation therapies;
food and beverages, including snacks, protein drinks, and
water; FDA-approved home testing kits for viral hepatitis,
including HBV and HCV, and HIV; distribution mechanisms,
such as bags for naloxone or safer sex kits and metal boxes
or containers for holding naloxone, for harm reduction

10400HB4039ham001 - 14 - LRB104 13076 BDA 35911 a
supplies, including stock as otherwise described and
delineated on this list;
(2) contingency management services, in which tangible
incentives are provided to participants contingent on
evidence of change in a specific, incentivized behavior
such as abstinence from a particular drug;
(3) services to promote hygiene and other basic needs,
including, but not limited to, mobile showers and clothing
distribution; and
(4) other services necessary to promote harm
reduction, as determined by the harm reduction provider
and approved by the Department.
(g) Harm reduction providers receiving grants under this
Act may utilize funds for the following activities, subject to
approval by the Department:
(1) compensation and fringe benefits for harm
reduction staff and supervisors;
(2) research and evaluation;
(3) community outreach and education; and
(4) building capacity in the harm reduction field.
(h) Harm reduction providers receiving grants under this
Act shall ensure that services are accessible to individuals
with disabilities and to individuals with limited English
proficiency. Harm reduction providers receiving grants under
this Act shall not deny services to individuals on the basis of
immigration status, gender identity, or any other protected

10400HB4039ham001 - 15 - LRB104 13076 BDA 35911 a
class.
(i) Communications that are made between a harm reduction
provider receiving a grant under this Act and an eligible
participant and while providing harm reduction services are
confidential and privileged. Except with the written consent
of the participant, a harm reduction provider shall not be
required to disclose such communications or related records in
any civil, criminal, administrative, or legislative
proceeding, nor shall the provider be examined regarding such
communications. Nothing in this subsection shall be construed
to supersede or conflict with federal confidentiality
requirements, including the Health Insurance Portability and
Accountability Act of 1996 and 42 CFR Part 2.
(j) The Department shall encourage harm reduction
providers receiving grants under this Act to employ people
with lived or living experience.
(k) Nothing in this Act shall be construed to supersede
the requirements of the Grant Accountability and Transparency
Act.
Article 4. Administrative Oversight
Section 4-5. Administration of harm reduction programming
and funding.
(a) The Department of Public Health shall administer harm
reduction programming and funding in coordination with other

10400HB4039ham001 - 16 - LRB104 13076 BDA 35911 a
State agencies, including the Department of Human Services, to
ensure that resources are expended effectively.
(b) No later than June 30, 2027, the Department of Public
Health and the Department of Human Services shall enter into
an interagency agreement outlining their shared and distinct
responsibilities for harm reduction in Illinois. The Harm
Reduction Advisory Board must provide advice on the
interagency agreement.
(c) Nothing in this Act shall be construed to require
existing harm reduction programming or funding to be
transferred from one State agency to another, for existing
programming or funding to be terminated or modified, or to
prevent State agencies from implementing new harm reduction
programming or funding in the future.
Article 5. Training, Technical Assistance, and Education
Section 5-5. Role of harm reduction providers.
Organizations or agencies that do not meet the definition of
harm reduction provider must subcontract with a harm reduction
provider to meet any requirements for harm reduction
programming, training, education, or technical assistance
established under this Act.
Section 5-10. Local government training. The Department
and the Harm Reduction Advisory Board may establish a program

10400HB4039ham001 - 17 - LRB104 13076 BDA 35911 a
to provide comprehensive education and training, for local
government agencies, including law enforcement and court
stakeholders, concerning this Act and the Overdose Prevention
and Harm Reduction Act, with a focus on ensuring compliance
with laws that provide immunity for participants, harm
reduction providers, and harm reduction staff and volunteers.
Article 6. Place-Based Approach to Harm Reduction
Section 6-5. Intent; purpose. This Article creates a
place-based approach to expand harm reduction education and
training, community engagement, mobile outreach, and
medication-assisted treatment in the communities with the
highest levels of overdoses and greatest unmet need for harm
reduction services.
Section 6-10. Pilot.
(a) The Department may make grants to one harm reduction
provider in a community in each Department region to
coordinate a place-based approach to harm reduction.
(b) Harm reduction providers receiving grants under this
Article shall provide the following services directly, through
subgrants to other organizations, or in coordination with
organizations receiving funding from other sources:
(1) community education and engagement on harm
reduction;

10400HB4039ham001 - 18 - LRB104 13076 BDA 35911 a
(2) mobile outreach to the populations at highest risk
of overdose; and
(3) provision of or referral to medication-assisted
treatment.
(c) Harm reduction providers receiving grants under this
Article may provide other services as necessary to expand harm
reduction and prevent overdose in the community, either
directly, through subgrants to other organizations, or in
coordination with organizations receiving funding from other
sources, as determined by the harm reduction provider and
approved by the Department.
(d) The harm reduction provider shall provide training and
technical assistance on harm reduction to subgrantees and
other collaborating organizations.
(e) Harm reduction providers receiving grants under this
Article and collaborating organizations are prohibited from
sharing information about participants with law enforcement
and from undertaking activities to increase arrests or
prosecutions for drug-related offenses or of people who use
drugs.
Section 6-15. Community selection. The Department shall
determine communities for the pilot by considering the
following factors:
(1) community population and poverty level;
(2) the geographic size of a community;

10400HB4039ham001 - 19 - LRB104 13076 BDA 35911 a
(3) the number of fatal and nonfatal overdoses in the
community;
(4) recent trends in the number of overdoses in the
community;
(5) the number of harm reduction providers in the
community; and
(6) how many people are served by harm reduction
providers in the community.
Article 7. Correctional Facilities
Section 7-5. Incarceration; naloxone. Naloxone shall be
made readily available to all correctional staff, health care
staff, other staff, and incarcerated individuals in all
prisons and jails, subject to the availability of funding to
support the prison or jail in obtaining a supply of naloxone.
Article 8. Health Care Facilities
Section 8-5. Medication for opioid use disorder. All acute
care hospitals that provide emergency services in an emergency
department, all satellite emergency facilities, and all
inpatient behavioral health treatment providers shall
maintain, as part of their services, protocols and capacity to
provide appropriate, evidence-based interventions prior to
discharge that reduce the risk of subsequent harm and fatality

10400HB4039ham001 - 20 - LRB104 13076 BDA 35911 a
following an opioid-related overdose, including, but not
limited to, institutional protocols and capacity to possess,
dispense, administer, and prescribe all FDA-approved
medications for opioid use disorder. Such treatment shall be
offered to all patients who present in an acute care hospital
emergency department, a satellite emergency facility, or
inpatient behavioral health treatment provider for care and
treatment of an opioid-related overdose or opioid use
disorder; provided, however, that treatment shall only occur
when it is recommended by the treating health care provider
and is voluntarily agreed to by the patient. Acute care
hospitals that provide emergency services in an emergency
department, satellite emergency facilities, and inpatient
behavioral health treatment providers shall demonstrate
compliance with applicable training and waiver requirements
established by the federal Drug Enforcement Administration and
the federal Substance Abuse and Mental Health Services
Administration relative to prescribing medication for opioid
use disorder. Prior to discharge, any patient who is
administered or prescribed medication for opioid use disorder
in an acute care hospital emergency department, satellite
emergency facility, or inpatient behavioral health treatment
provider shall be directly connected to an appropriate
provider or treatment site to voluntarily continue the
treatment. This requirement can be met through partnership
with medication on demand available through the Illinois

10400HB4039ham001 - 21 - LRB104 13076 BDA 35911 a
Helpline operated by the Department of Human Services or a
provider licensed to provide medication-assisted recovery in
accordance with 77 Ill. Adm. Code 2060.
Section 8-10. Patient discharge and education on naloxone;
provider referral. Upon discharge of a patient from an acute
care hospital, satellite emergency facility, or inpatient
behavioral health treatment provider who has: (i) a history of
or is actively using opioids or other illicit drugs; (ii) been
diagnosed with opioid use disorder; or (iii) experienced an
opioid-related overdose, the acute care hospital, satellite
emergency facility, or inpatient behavioral health treatment
provider shall educate the patient on the use of naloxone,
offer not less than 2 doses of naloxone to the patient or a
legal guardian of the patient, subject to the availability of
funding to support the hospital in obtaining a supply of
naloxone, and provide information about a harm reduction
provider and offer to directly connect the patient to a harm
reduction provider.
Section 8-15. Rulemaking. The Department may adopt rules
for the implementation of this Article.
Article 9. Housing
Section 9-5. Recovery homes. A recovery home licensed in

10400HB4039ham001 - 22 - LRB104 13076 BDA 35911 a
accordance with 77 Ill. Adm. Code 2060 must comply with the
following requirements:
(1) A resident may not be evicted for a single
recurrence of substance use disorder symptoms. Other
behaviors while intoxicated that violate the terms of
residency may be grounds for rejection of an applicant for
housing or eviction of a resident.
(2) If an applicant is rejected or a resident is
evicted solely based on abstinence-only or sobriety
requirements, the recovery home shall identify another
housing provider that will accept the individual and
directly connect the individual to that housing provider.
(3) Discrimination against applicants solely on the
basis of criminal records, records of arrests, charges, or
convictions on drug-related offenses is prohibited.
Section 9-10. Housing evictions based on opioid use
disorder treatment. All operators or owners of housing are
prohibited from rejecting applicants or evicting residents
because they are receiving medication for opioid use disorder
or other forms of medication-assisted treatment.
Section 9-15. Federal requirements. Nothing in this
Article shall be construed to prohibit a housing provider from
complying with federal laws or regulations if housing is
provided using both federal and State funding.

10400HB4039ham001 - 23 - LRB104 13076 BDA 35911 a
Article 10. Home Rule Preemption
Section 10-5. Home rule preemption.
(a) A home rule unit may not prohibit the establishment or
operation of any harm reduction activities as provided in this
Act.
(b) A municipality may not adopt zoning regulations for
the sole purpose of prohibiting the establishment or operation
of any harm reduction activities as provided in this Act.
(c) This Section is a denial and limitation of home rule
powers and functions under subsection (g) of Section 6 of
Article VII of the Illinois Constitution.
Article 11. Amendatory Provisions
Section 11-5. The Department of Professional Regulation
Law of the Civil Administrative Code of Illinois is amended by
adding Section 2105-372 as follows:
(20 ILCS 2105/2105-372 new)
Sec. 2105-372. Continuing education; harm reduction.
(a) As used in this Section:
"Harm reduction" means a philosophical framework and set
of strategies designed to reduce harm and promote dignity and
well-being among persons and communities who engage in

10400HB4039ham001 - 24 - LRB104 13076 BDA 35911 a
substance use.
"Harm reduction professional" has the meaning given to
that term in the Holistic Overdose Prevention and Equity Act.
"Harm reduction provider" has the meaning given to that
term in the Holistic Overdose Prevention and Equity Act.
"Health care professional" means a person licensed or
registered by the Department under the following Acts: the
Medical Practice Act of 1987, the Nurse Practice Act, the
Clinical Psychologist Licensing Act, the Illinois Optometric
Practice Act of 1987, the Illinois Physical Therapy Act, the
Pharmacy Practice Act, the Physician Assistant Practice Act of
1987, the Clinical Social Work and Social Work Practice Act,
the Nursing Home Administrators Licensing and Disciplinary
Act, the Illinois Occupational Therapy Practice Act, the
Podiatric Medical Practice Act of 1987, the Respiratory Care
Practice Act, the Professional Counselor and Clinical
Professional Counselor Licensing and Practice Act, the
Illinois Speech-Language Pathology and Audiology Practice Act,
the Illinois Dental Practice Act, the Marriage and Family
Therapy Licensing Act, or the Behavior Analyst Licensing Act.
(b) For health care professional license or registration
renewals occurring on or after January 1, 2027, a health care
professional who has continuing education requirements must
complete at least a one-hour course or training on harm
reduction per renewal period. A health care professional may
count this one hour for completion of this course toward

10400HB4039ham001 - 25 - LRB104 13076 BDA 35911 a
meeting the minimum credit hours required for continuing
education.
(c) Any course or training offered to meet the
requirements of this Section must be designed by or delivered
by a harm reduction provider or harm reduction professional.
(d) The Department may adopt rules for the implementation
of this Section.
Section 11-10. The Counties Code is amended by adding
Section 3-6043 as follows:
(55 ILCS 5/3-6043 new)
Sec. 3-6043. Release; naloxone. Upon the release of a
prisoner from a correctional institution, the sheriff shall
provide the prisoner with naloxone, subject to the
availability of funding, and a referral to a harm reduction
provider, as well as to the substance use disorder treatment
provider the prisoner was receiving treatment from prior to
incarceration or a new provider, if that is the individual's
preference, if applicable. In counties with more than 3
million residents that have a county hospital system that
provides correctional health services, the county hospital
system shall also have a role, as determined by the sheriff, in
providing individuals being released from a county
correctional institution with naloxone and a referral to a
harm reduction provider.

10400HB4039ham001 - 26 - LRB104 13076 BDA 35911 a
Section 11-15. The Unified Code of Corrections is amended
by changing Section 3-14-1 as follows:
(730 ILCS 5/3-14-1) (from Ch. 38, par. 1003-14-1)
Sec. 3-14-1. Release from the institution.
(a) Upon release of a person on parole, mandatory release,
final discharge, or pardon, the Department shall return all
property held for him, provide him with suitable clothing and
procure necessary transportation for him to his designated
place of residence and employment. It may provide such person
with a grant of money for travel and expenses which may be paid
in installments. The amount of the money grant shall be
determined by the Department.
(a-1) The Department shall, before a wrongfully imprisoned
person, as defined in Section 3-1-2 of this Code, is
discharged from the Department, provide him or her with any
documents necessary after discharge.
(a-2) The Department of Corrections may establish and
maintain, in any institution it administers, revolving funds
to be known as "Travel and Allowances Revolving Funds". These
revolving funds shall be used for advancing travel and expense
allowances to committed, paroled, and discharged prisoners.
The moneys paid into such revolving funds shall be from
appropriations to the Department for Committed, Paroled, and
Discharged Prisoners.

10400HB4039ham001 - 27 - LRB104 13076 BDA 35911 a
(a-3) Upon release of a person who is eligible to vote on
parole, mandatory release, final discharge, or pardon, the
Department shall provide the person with a form that informs
him or her that his or her voting rights have been restored and
a voter registration application. The Department shall have
available voter registration applications in the languages
provided by the Illinois State Board of Elections. The form
that informs the person that his or her rights have been
restored shall include the following information:
(1) All voting rights are restored upon release from
the Department's custody.
(2) A person who is eligible to vote must register in
order to be able to vote.
The Department of Corrections shall confirm that the
person received the voter registration application and has
been informed that his or her voting rights have been
restored.
(a-4) Prior to release of a person on parole, mandatory
supervised release, final discharge, or pardon, the Department
shall screen every person for Medicaid eligibility. Officials
of the correctional institution or facility where the
committed person is assigned shall assist an eligible person
to complete a Medicaid application to ensure that the person
begins receiving benefits as soon as possible after his or her
release. The application must include the eligible person's
address associated with his or her residence upon release from

10400HB4039ham001 - 28 - LRB104 13076 BDA 35911 a
the facility. If the residence is temporary, the eligible
person must notify the Department of Human Services of his or
her change in address upon transition to permanent housing.
(a-5) Upon release of a person from its custody to parole,
upon mandatory supervised release, or upon final discharge,
the Department shall run a LEADS report and shall notify the
person of all in-effect protective orders issued against the
person under Article 112A of the Code of Criminal Procedure of
1963 or under the Illinois Domestic Violence Act of 1986, the
Civil No Contact Order Act, or the Stalking No Contact Order
Act, that are identified in the LEADS report.
(b) (Blank).
(c) Except as otherwise provided in this Code, the
Department shall establish procedures to provide written
notification of any release of any person who has been
convicted of a felony to the State's Attorney and sheriff of
the county from which the offender was committed, and the
State's Attorney and sheriff of the county into which the
offender is to be paroled or released. Except as otherwise
provided in this Code, the Department shall establish
procedures to provide written notification to the proper law
enforcement agency for any municipality of any release of any
person who has been convicted of a felony if the arrest of the
offender or the commission of the offense took place in the
municipality, if the offender is to be paroled or released
into the municipality, or if the offender resided in the

10400HB4039ham001 - 29 - LRB104 13076 BDA 35911 a
municipality at the time of the commission of the offense. If a
person convicted of a felony who is in the custody of the
Department of Corrections or on parole or mandatory supervised
release informs the Department that he or she has resided,
resides, or will reside at an address that is a housing
facility owned, managed, operated, or leased by a public
housing agency, the Department must send written notification
of that information to the public housing agency that owns,
manages, operates, or leases the housing facility. The written
notification shall, when possible, be given at least 14 days
before release of the person from custody, or as soon
thereafter as possible. The written notification shall be
provided electronically if the State's Attorney, sheriff,
proper law enforcement agency, or public housing agency has
provided the Department with an accurate and up to date email
address.
(c-1) (Blank).
(c-2) The Department shall establish procedures to provide
notice to the Illinois State Police of the release or
discharge of persons convicted of violations of the
Methamphetamine Control and Community Protection Act or a
violation of the Methamphetamine Precursor Control Act. The
Illinois State Police shall make this information available to
local, State, or federal law enforcement agencies upon
request.
(c-5) If a person on parole or mandatory supervised

10400HB4039ham001 - 30 - LRB104 13076 BDA 35911 a
release becomes a resident of a facility licensed or regulated
by the Department of Public Health, the Illinois Department of
Public Aid, or the Illinois Department of Human Services, the
Department of Corrections shall provide copies of the
following information to the appropriate licensing or
regulating Department and the licensed or regulated facility
where the person becomes a resident:
(1) The mittimus and any pre-sentence investigation
reports.
(2) The social evaluation prepared pursuant to Section
3-8-2.
(3) Any pre-release evaluation conducted pursuant to
subsection (j) of Section 3-6-2.
(4) Reports of disciplinary infractions and
dispositions.
(5) Any parole plan, including orders issued by the
Prisoner Review Board, and any violation reports and
dispositions.
(6) The name and contact information for the assigned
parole agent and parole supervisor.
This information shall be provided within 3 days of the
person becoming a resident of the facility.
(c-10) If a person on parole or mandatory supervised
release becomes a resident of a facility licensed or regulated
by the Department of Public Health, the Illinois Department of
Public Aid, or the Illinois Department of Human Services, the

10400HB4039ham001 - 31 - LRB104 13076 BDA 35911 a
Department of Corrections shall provide written notification
of such residence to the following:
(1) The Prisoner Review Board.
(2) The chief of police and sheriff in the
municipality and county in which the licensed facility is
located.
The notification shall be provided within 3 days of the
person becoming a resident of the facility.
(d) Upon the release of a committed person on parole,
mandatory supervised release, final discharge, or pardon, the
Department shall provide such person with information
concerning programs and services of the Illinois Department of
Public Health to ascertain whether such person has been
exposed to the human immunodeficiency virus (HIV) or any
identified causative agent of Acquired Immunodeficiency
Syndrome (AIDS).
(d-5) Upon the release of a committed person from a
correctional institution or facility, the Department shall
provide the committed person with naloxone and a referral to a
harm reduction provider, as that term is defined in the
Holistic Overdose Prevention and Equity Act, as well as to the
substance use disorder treatment provider the prisoner was
receiving treatment from prior to incarceration or a new
provider, if that is the individual's preference, if
applicable.
(e) Upon the release of a committed person on parole,

10400HB4039ham001 - 32 - LRB104 13076 BDA 35911 a
mandatory supervised release, final discharge, pardon, or who
has been wrongfully imprisoned, the Department shall verify
the released person's full name, date of birth, and social
security number. If verification is made by the Department by
obtaining a certified copy of the released person's birth
certificate and the released person's social security card or
other documents authorized by the Secretary, the Department
shall provide the birth certificate and social security card
or other documents authorized by the Secretary to the released
person. If verification by the Department is done by means
other than obtaining a certified copy of the released person's
birth certificate and the released person's social security
card or other documents authorized by the Secretary, the
Department shall complete a verification form, prescribed by
the Secretary of State, and shall provide that verification
form to the released person.
(f) Forty-five days prior to the scheduled discharge of a
person committed to the custody of the Department of
Corrections, the Department shall give the person:
(1) who is otherwise uninsured an opportunity to apply
for health care coverage including medical assistance
under Article V of the Illinois Public Aid Code in
accordance with subsection (b) of Section 1-8.5 of the
Illinois Public Aid Code, and the Department of
Corrections shall provide assistance with completion of
the application for health care coverage including medical

10400HB4039ham001 - 33 - LRB104 13076 BDA 35911 a
assistance;
(2) information about obtaining a standard Illinois
Identification Card or a limited-term Illinois
Identification Card under Section 4 of the Illinois
Identification Card Act if the person has not been issued
an Illinois Identification Card under subsection (a-20) of
Section 4 of the Illinois Identification Card Act;
(3) information about voter registration and may
distribute information prepared by the State Board of
Elections. The Department of Corrections may enter into an
interagency contract with the State Board of Elections to
participate in the automatic voter registration program
and be a designated automatic voter registration agency
under Section 1A-16.2 of the Election Code;
(4) information about job listings upon discharge from
the correctional institution or facility;
(5) information about available housing upon discharge
from the correctional institution or facility;
(6) a directory of elected State officials and of
officials elected in the county and municipality, if any,
in which the committed person intends to reside upon
discharge from the correctional institution or facility;
and
(7) any other information that the Department of
Corrections deems necessary to provide the committed
person in order for the committed person to reenter the

10400HB4039ham001 - 34 - LRB104 13076 BDA 35911 a
community and avoid recidivism.
(g) Sixty days before the scheduled discharge of a person
committed to the custody of the Department or upon receipt of
the person's certified birth certificate and social security
card as set forth in subsection (d) of Section 3-8-1 of this
Act, whichever occurs later, the Department shall transmit an
application for an Identification Card to the Secretary of
State, in accordance with subsection (a-20) of Section 4 of
the Illinois Identification Card Act.
The Department may adopt rules to implement this Section.
(Source: P.A. 103-345, eff. 1-1-24; 104-11, eff. 6-20-25.)
Section 11-20. The County Jail Act is amended by adding
Sections 19.7 and 19.9 as follows:
(730 ILCS 125/19.7 new)
Sec. 19.7. Release; naloxone. Upon the release of a
prisoner from a jail, the warden shall provide the prisoner
with naloxone, subject to the availability of funding to
support the jail in obtaining a supply of naloxone, and a
referral to a harm reduction provider, as that term is defined
in the Holistic Overdose Prevention and Equity Act, as well as
to the substance use disorder treatment provider the prisoner
was receiving treatment from prior to incarceration or a new
provider, if that is the individual's preference, if
applicable. In counties with more than 3 million residents

10400HB4039ham001 - 35 - LRB104 13076 BDA 35911 a
that have a county hospital system that provides correctional
health services, the county hospital system shall also have a
role, as determined by the warden, in providing individuals
being released from a county correctional institution with
naloxone and a referral to a harm reduction provider.
(730 ILCS 125/19.9 new)
Sec. 19.9. Medication for opioid use disorder.
(a) In this Section:
"Clinically indicated" means a medical procedure or
treatment is based upon the treatment provider's medical
judgment in accordance with the current generally accepted
standards of care.
"Medication-assisted treatment" means the use of
FDA-approved medications, in combination with counseling and
behavioral therapies, to provide a whole patient approach to
the treatment of substance use disorders.
"Medications for opioid use disorder" means the use of
FDA-approved medications to treat substance use disorders.
(b) Within 24 hours of admission to a jail, each detained
person shall be screened for substance use disorders as part
of an initial and ongoing substance use screening and
assessment process. This process includes screening and
assessment for opioid use disorders.
(c) A detained person who is admitted to a jail while under
the medical care of a physician licensed to practice medicine

10400HB4039ham001 - 36 - LRB104 13076 BDA 35911 a
in all of its branches, a licensed physician assistant, or a
licensed advanced practice registered nurse and who is taking
medication at the time of admission in accordance with a valid
prescription, as verified by the individual's pharmacy of
record, primary care provider, other licensed care provider,
or a prescription monitoring or information system, shall have
that medication continued and provided by the jail pending an
evaluation by a physician licensed to practice medicine in all
of its branches, a licensed physician assistant, or a licensed
advanced practice registered nurse and subject to the
treatment provider's medical judgment. The jail may defer
provision of a validly prescribed medication in accordance
with this subsection if, in the judgment of a physician
licensed to practice medicine in all of its branches, a
licensed physician assistant, or a licensed advanced practice
registered nurse, continuation of the medication is no longer
clinically indicated.
A detained person who is admitted to a jail while under the
medical care of a physician licensed to practice medicine in
all of its branches, a licensed physician assistant, or a
licensed advanced practice registered nurse and who is taking
medication for an opioid use disorder or participating in
medication-assisted treatment at the time of admission in
accordance with a valid prescription, as verified by the
individual's pharmacy of record, primary care provider, other
licensed care provider, or a prescription monitoring or

10400HB4039ham001 - 37 - LRB104 13076 BDA 35911 a
information system, shall have the detained person's
medication continued and provided by the jail pending an
evaluation by a physician licensed to practice medicine in all
of its branches, a licensed physician assistant, or a licensed
advanced practice registered nurse and subject to the
treatment provider's medical judgment. The jail may defer
provision of a validly prescribed medication in accordance
with this subsection if, in the judgment of a physician
licensed to practice medicine in all of its branches, a
licensed physician assistant, or a licensed advanced practice
registered nurse, continuation of the medication is no longer
clinically indicated. An individual participating in a
medication-assisted treatment program may have counseling and
behavioral therapies continued to the extent possible.
If at any time a detained person screens positive as
having or being at risk for an opioid use disorder, is
diagnosed with an opioid use disorder, or is exhibiting
symptoms of withdrawal from an opioid use disorder and if
medication-assisted treatment is clinically indicated by a
physician licensed to practice medicine in all of its
branches, a licensed physician assistant, or a licensed
advanced practice registered nurse, then the individual may
consent to commence medications for opioid use disorder, which
shall be provided by the jail. The detained person shall be
authorized to receive the medication without delay and for as
long as clinically indicated.

10400HB4039ham001 - 38 - LRB104 13076 BDA 35911 a
(d) The licensed practitioner who makes the clinical
judgment to discontinue the use of medication shall enter the
reason for the discontinuance into the detained person's
medical record, specifically stating the reason for
discontinuance. The individual shall be provided, both orally
and in writing, with a specific explanation of the decision to
discontinue the medication.
(e) As part of the reentry planning, the jail shall
commence medications for opioid use disorder prior to an
individual's release if:
(1) the individual screens positive as having an
opioid use disorder, being at risk for an opioid use
disorder, or exhibiting symptoms of withdrawal from an
opioid use disorder;
(2) medication-assisted treatment is clinically
indicated by a physician licensed to practice medicine in
all of its branches, a licensed physician assistant, or a
licensed advanced practice registered nurse; and
(3) the individual consents to commence medications
for opioid use disorder.
Upon reentry, the jail shall provide an individual
participating in medication-assisted treatment with a referral
to a provider in the community who may assist the individual
with continued medications for opioid use disorder and
medication-assisted treatment care.
(f) The jail shall offer, or facilitate access to, all

10400HB4039ham001 - 39 - LRB104 13076 BDA 35911 a
medication-assisted treatment options deemed appropriate for
an individual by an authorized health care professional. The
jail shall not impose limitations on the types of
medication-assisted treatment that may be recommended by an
authorized health care professional as part of an individual's
treatment plan.
(g) This Section shall not apply to an individual jail
until the jail has been approved by the Department of
Healthcare and Family Services for provision of reentry
services under federal Medicaid waiver authorities, including
Section 1115 of the Social Security Act.
Section 11-25. The Overdose Prevention and Harm Reduction
Act is amended by adding Section 20 as follows:
(410 ILCS 710/20 new)
Sec. 20. Home rule preemption. A home rule unit may not
prohibit the establishment or operation of a needle and
hypodermic syringe access program as provided in this Act.
This Section is a denial and limitation of home rule powers and
functions under subsection (g) of Section 6 of Article VII of
the Illinois Constitution.".